Answers are grounded in this paper and cite their sources.
Review assesses RNA biosensor advancements for diabetes care and endocrine disruptor effects on diagnostics.
The advancements in the areas of real-time RNA biosensor technology and their application to more precise diabetes care have laid the groundwork for new and potentially efficient strategies for monitoring and management of the disease. At the same time, many researchers are now studying the influence of environmental factors, and more specifically, exposure to endocrine-disrupting chemicals (EDCs), that can impact not only the diabetes disease process itself, but also the reliability and consistency of biosensors to monitor these stressors. The current review summarizes recent advances in RNA sensor technology designed for diabetes care, evaluates the connection between it and point-of-care (POC) diagnostics, and purposefully analyzes the existing evidence on how such EDCs can affect biosensor accuracy, stability, and general clinical usefulness.
No takes yet. Share an insight, caveat, or question.
Ashara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: